$8 Billion Risperdal Judgment Reduced to $6.8 Million

The judge presiding over a case which saw Johnson & Johnson hit with an $8bn jury verdict has reduced the amount the company has to pay in damages to $6.8m.

Last October, J&J was ordered to pay $8bn in damages to a US man who claims he was not warned that taking the company’s antipsychotic Risperdal could lead to breast growth.

A jury in Philadelphia agreed with the allegation that J&J’s Janssen unit had downplayed the risk that use of Risperdal (risperidone) in male children can cause enlarged breasts, a condition known as gynaecomastia.

Stanford Law Experts on Johnson & Johnson Product Liability Exposure

Johnson & Johnson is facing tens of thousands of product liability lawsuits, involving, among other things, its antipsychotic drug Risperdal, opioids, vaginal mesh, and talcum powder.

Here, Stanford Law Professor Nora Freeman Engstrom, a tort law and complex litigation expert, and Diana Garnet Li, a student in the Stanford Law School Class of 2021, discuss the mounting product liability exposure facing the multinational giant—and how these cases may develop.

Scroll to Top